HIV Treatment and Prevention Agents and Patient Care

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

HIV Treatment and Prevention Agents

Patient Care

FDA Approves Meloxicam Injection For Moderate-to-Severe Pain in Adults

Pharmacy Times

JUNE 10, 2025

1 "[Meloxicam injection] demonstrates our commitment to improving patient care by providing an alternate dosage form for pain management," Ron Scarboro, chief executive officer at Azurity Pharmaceuticals, said in a press release. 2 REFERENCES 1. Meloxicam: Selective COX-2 inhibition in clinical practice. December 21, 2004.

FDA

FDA HIV Treatment and Prevention Agents Compounding Pharmacies Hospitals

Pharma’s post-pandemic launch performance problem: what’s the prognosis?

pharmaphorum

JUNE 29, 2022

COVID vaccines and treatments have created a substantial market over and above the existing Rx market- IQVIA estimates that the cumulative value of COVID vaccines could be between $185 and 295bn to 2026. The initial pandemic lockdowns prevented many patients from seeing doctors face-to-face.

HIV Treatment and Prevention Agents

HIV Treatment and Prevention Agents Pharmaceutical Companies Pharmaceutical Companies Vaccines

Pharmacy Technician Pulse

FDA Approves Meloxicam Injection For Moderate-to-Severe Pain in Adults

Pharma’s post-pandemic launch performance problem: what’s the prognosis?

Stay Connected